Testosterone Cypionate generic
testosterone cypionate is an androgen and anabolic steroid medication owned by Slayback Pharma Llc. The drug contains the active ingredient testosterone cypionate and is available in solution; intramuscular dosage forms. It was first authorized for market use on June 2, 2022. testosterone cypionate has a total of 2 patents, both of which are set to expire on March 25, 2039.
When will Testosterone Cypionate generic be available?
The Testosterone Cypionate generic is expected to be available after the expiry of the last patent on March 25, 2039. The two patents, US11311554 and US11642355, both titled 'Pharmaceutical compositions of testosterone', ensure the exclusivity of Testosterone Cypionate until that date.
Testosterone Cypionate uses
testosterone cypionate is primarily used for testosterone replacement therapy in men who have conditions associated with symptoms of deficiency in the hormone or absence of endogenous testosterone. The active ingredient, testosterone cypionate, is a synthetic version of the naturally produced testosterone hormone and assists in various bodily functions including hair growth, bone density, libido, muscle mass and fat distribution.
Testosterone Cypionate patent expiration
Testosterone Cypionate is protected by two patents, both expiring on March 25, 2039. These patents, US11311554 and US11642355, are titled 'Pharmaceutical compositions of testosterone'. After the expiry of these patents, the market for Testosterone Cypionate generic versions will open. Below are the details of the patents: